NEW YORK, April 7 (GenomeWeb News) - CellCentric of Cambridge, UK, will use a £250,000 ($470,000) grant obtained from the Rainbow Seed Fund to help it participate in an epigenetics collaboration with Babraham Institute, the company said today.
Under the agreement with Babraham, CellCentric will use its discovery platform to develop a variety of products on proteins and small molecules involved in cancer, and will receive exclusive rights to epigenetic-related intellectual property generated at the institute. Additionally, CellCentric will fund the research of the lab of Wolf Reik of the institute to generate research reagents for biomanufacturing and disease modeling.
Further financial details were not disclosed.
The Rainbow Seed Fund disburses a fund established by the UK's Office of Science and Technology and to support early-stage firms springing out of the research institutes of the Biotechnology and Biological Sciences Research Council.